ClinicalTrials.gg
CompletedNCT00642811RESPONDUpdated Oct 4, 2011Results posted

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

A Phase 2 interventional study of Ticagrelor and Clopidogrel in Stable Coronary Artery Disease, sponsored by AstraZeneca. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-04.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.

Enrollment
32nd of 78
98 · median 80
Started
2008
with 1 other
Phase 2
7 of 78
none open now
Registered
3rd of 78
by date
Lead sponsor
9 of 78
AstraZeneca

Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 32nd largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 2, and was the 3rd registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing ticagrelor in Coronary Artery Disease, or all of them as a file.
02

Study summary

The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated the effect of Ticagrelor on inhibition of platelet aggregation compared with clopidogrel in patients previously identified as non-responsive to clopidogrel.

03

Conditions studied

  • Stable Coronary Artery Disease

Keywords

  • coronary artery disease (CAD)
  • heart attack
  • stable angina
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with documented stable Coronary Artery Disease (CAD) (stable angina, previous MI history, previous history of revascularization)
  • Females of child bearing potential must have a negative pregnancy test prior to receiving study drug and be willing to use a hormonal in addition to double barrier contraception

Exclusion criteria

Exclusion Criteria:

  • History of Acute Coronary Syndromes within 12 months of screening or need for revascularization (angioplasty or coronary artery bypass graft (CABG))
  • Any acute or chronic unstable condition in the past 30 days
  • Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high blood pressure, low count, recent major trauma
  • History of intolerance or allergy to aspirin or clopidogrel
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    1

    Aspirin + Ticagrelor

    Drug: Ticagrelor · Drug: Aspirin

  • Active comparator
    2

    Aspirin + Clopidogrel

    Drug: Clopidogrel · Drug: Aspirin

Interventions

  • Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks

  • (over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks

    Also known as: Plavix

  • Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study

06

What researchers measure

Primary outcomes

  1. Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.)

    The primary definition of response to treatment is IPA \>10% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: Day 14 and Day 28, 4 Hrs Post Dose.

  2. Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.

    The secondary definition of response to treatment is IPA \>50% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: Day 14, and day 28, 4 hours post dose

Secondary outcomes

  1. Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 15

    IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.

    Time frame: Day 15, 4 hrs post switching

  2. Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 28

    IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.

    Time frame: 4 hrs post first dose on day 28

  3. Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 15

    IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.

    Time frame: Day 15, 4 hrs post switching

  4. Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 28

    IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.

    Time frame: 4 hrs post first dose on day 28

07

Results

Posted Oct 4, 2011

Participant flow

Participant flow — Overall Study
MilestoneClopidogrel Non-responders - Clopidogrel to TicagrelorClopidogrel Non-responders - Ticagrelor to ClopidogrelClopidogrel Responders - Clopidogrel to ClopidogrelClopidogrel Responders - Clopidogrel to TicagrelorClopidogrel Responders - Ticagrelor to ClopidogrelClopidogrel Responders - Ticagrelor to Ticagrelor
Started202113161414
Completed171713151313
Not completed340111
Withdrew: Adverse event230001
Withdrew: Developement of discontinuation criteria000010
Withdrew: Severe non-compliance to protocol100000
Withdrew: Other010100

Outcome measures

PrimaryProportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.)

The primary definition of response to treatment is IPA \>10% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
Day 14 and Day 28, 4 Hrs Post Dose.
Reported as:
Number · Percent of Participants
Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.)
Percent of ParticipantsNon-responder: TicagrelorNon-responder: Clopidogrel
Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.)10093.8
PrimaryProportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.

The secondary definition of response to treatment is IPA \>50% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
Day 14, and day 28, 4 hours post dose
Reported as:
Number · Percent of participants
Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.
Percent of participantsNon-responder: TicagrelorNon-responder: Clopidogrel
Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.81.325.0
SecondaryClopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 15

IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.

Time frame:
Day 15, 4 hrs post switching
Reported as:
Least squares mean · Percent
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 15
PercentResponder: TicagrelorResponder: Clopidogrel
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 1566.7 (49.7 to 83.7)65.3 (46.5 to 84.2)
SecondaryClopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 28

IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.

Time frame:
4 hrs post first dose on day 28
Reported as:
Least squares mean · Percent
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 28
PercentResponder: TicagrelorResponder: Clopidogrel
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 2891.0 (77.1 to 104.9)61.2 (46.4 to 76.0)
SecondaryClopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 15

IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.

Time frame:
Day 15, 4 hrs post switching
Reported as:
Least squares mean · Percent
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 15
PercentResponder: TicagrelorResponder: Clopidogrel
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 1595.0 (87.7 to 102.4)48.5 (40.8 to 56.2)
SecondaryClopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 28

IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.

Time frame:
4 hrs post first dose on day 28
Reported as:
Least squares mean · Percent
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 28
PercentResponder: TicagrelorResponder: Clopidogrel
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 2877.4 (67.0 to 87.8)60.8 (49.9 to 71.7)

Adverse events

Collected over Switching Period - first 24 hrs (Day 15), patients switched study medication (from clop. to ticag. or vice versa). Non-Switching Period - Day 1-14 and Day 16-28.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clopidogrel Non-Responders/Non-Switching Period: Ticagrelor—2/39 (5.1%)13/39 (33.3%)
Clopidogrel Non-Responders/Non-Switching Period: Clopidogrel—0/38 (0%)13/39 (33.3%)
Clop. Non-Responders/Switching Period:Ticagrelor-Clopidogrel—0/18 (0%)1/18 (5.6%)
Clop. Non-Responders/Switching Period: Clopidogrel-Ticagrelor—0/18 (0%)4/18 (22.2%)
Clop. Responders/Non-Switching Period: Ticagrelor—2/44 (4.5%)19/44 (43.2%)
Clop. Responders/Non-Switching Period: Clopidogrel—0/42 (0%)14/42 (33.3%)
Clop. Responders/Switching Period: Ticagrelor-Clopidogrel—0/13 (0%)2/13 (15.4%)
Clop. Responders/Switching Period: Clopidogrel-Ticagrelor—0/16 (0%)1/16 (6.3%)
Most frequent serious events
Most frequent serious events
EventClopidogrel Non-Responders/Non-Switching Period: TicagrelorClopidogrel Non-Responders/Non-Switching Period: ClopidogrelClop. Non-Responders/Switching Period:Ticagrelor-ClopidogrelClop. Non-Responders/Switching Period: Clopidogrel-TicagrelorClop. Responders/Non-Switching Period: TicagrelorClop. Responders/Non-Switching Period: ClopidogrelClop. Responders/Switching Period: Ticagrelor-ClopidogrelClop. Responders/Switching Period: Clopidogrel-Ticagrelor
Myocardial InfarctionCardiac disorders1/390/380/180/180/440/420/130/16
HypotensionVascular disorders1/390/380/180/180/440/420/130/16
Atrial FibrillationCardiac disorders0/390/380/180/181/440/420/130/16
BradycardiaCardiac disorders0/390/380/180/181/440/420/130/16
Ventricular ExtrasystolesCardiac disorders0/390/380/180/181/440/420/130/16
Most frequent other events
Showing 10 of 17
Most frequent other events
EventClopidogrel Non-Responders/Non-Switching Period: TicagrelorClopidogrel Non-Responders/Non-Switching Period: ClopidogrelClop. Non-Responders/Switching Period:Ticagrelor-ClopidogrelClop. Non-Responders/Switching Period: Clopidogrel-TicagrelorClop. Responders/Non-Switching Period: TicagrelorClop. Responders/Non-Switching Period: ClopidogrelClop. Responders/Switching Period: Ticagrelor-ClopidogrelClop. Responders/Switching Period: Clopidogrel-Ticagrelor
DYSPNOEARespiratory, thoracic and mediastinal disorders7/393/381/182/186/440/420/130/16
DIZZINESSNervous system disorders1/393/380/182/181/441/420/130/16
DYSPEPSIAGastrointestinal disorders0/390/380/180/181/444/420/130/16
NAUSEAGastrointestinal disorders0/391/380/180/180/444/420/130/16
FATIGUEGeneral disorders0/391/380/180/181/442/421/130/16
ARTHRALGIAMusculoskeletal and connective tissue disorders0/390/380/180/180/441/421/130/16
MYALGIAMusculoskeletal and connective tissue disorders0/391/380/180/180/440/421/130/16
INCREASED TENDENCY TO BRUISESkin and subcutaneous tissue disorders3/391/380/180/182/442/420/131/16
CONTUSIONInjury, poisoning and procedural complications0/390/380/180/183/440/420/130/16
EPISTAXISRespiratory, thoracic and mediastinal disorders0/390/380/180/183/440/420/130/16

Baseline characteristics

Age Continuous
Age Continuous(year)Clopidogrel Non-responders - Clopidogrel to TicagrelorClopidogrel Non-responders - Ticagrelor to ClopidogrelClopidogrel Responders - Clopidogrel to ClopidogrelClopidogrel Responders - Clopidogrel to TicagrelorClopidogrel Responders - Ticagrelor to ClopidogrelClopidogrel Responders - Ticagrelor to TicagrelorTotal
Mean67.25 ± 8.1264.57 ± 6.3165.46 ± 8.6864.56 ± 8.5663.21 ± 9.2361.57 ± 8.2264.8 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)Clopidogrel Non-responders - Clopidogrel to TicagrelorClopidogrel Non-responders - Ticagrelor to ClopidogrelClopidogrel Responders - Clopidogrel to ClopidogrelClopidogrel Responders - Clopidogrel to TicagrelorClopidogrel Responders - Ticagrelor to ClopidogrelClopidogrel Responders - Ticagrelor to TicagrelorTotal
Female58323122
Male15131014111376
08

Study locations

10 sites
  • Research Site
    Jonesboro, Arkansas, United States
  • Research Site
    Ormond Beach, Florida, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Lachine, Canada
  • Research Site
    Aalborg, Denmark
  • Research Site
    Arhus, Denmark
  • Research Site
    Esbjerg, Denmark
  • Research Site
    Sheffield, United Kingdom
09

References and documents

Publications

  • Jeong YH, Bliden KP, Antonino MJ, Park KS, Tantry US, Gurbel PA. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am Heart J. 2012 Jul;164(1):35-42. doi: 10.1016/j.ahj.2012.03.022. Epub 2012 Jun 13. PubMed 22795280 ↗
  • Jeong YH, Bliden KP, Tantry US, Gurbel PA. High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? J Thromb Haemost. 2012 Mar;10(3):487-9. doi: 10.1111/j.1538-7836.2011.04604.x. No abstract available. PubMed 22212857 ↗
  • Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010 Dec;3(6):556-66. doi: 10.1161/CIRCGENETICS.110.958561. Epub 2010 Nov 15. PubMed 21079055 ↗
  • Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010 Mar 16;121(10):1188-99. doi: 10.1161/CIRCULATIONAHA.109.919456. Epub 2010 Mar 1. PubMed 20194878 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2008
First posted
Mar 25, 2008
Start
May 2008
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Oct 4, 2011
Last update
Oct 4, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00642811
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 25, 2008
Start date
May 2008
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Oct 4, 2011
Last update
Oct 4, 2011

Study contacts

Jay Horrow, MD
study director · AstraZeneca
Paul Gurbel, md
principal investigator · Platelet & Thrombosis Research, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion